COHERUS BIOSCIENCES I

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

04 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

02 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

27 9 2023 08:10:29 提供 Nasdaq GlobeNewswire

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

25 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

22 9 2023 20:00:00 提供 Nasdaq GlobeNewswire

Coherus Completes Surface Oncology Acquisition

08 9 2023 08:05:40 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Participate at Upcoming September Investor Conferences

01 9 2023 15:01:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

22 8 2023 16:35:22 提供 Nasdaq GlobeNewswire

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

02 8 2023 15:01:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

26 7 2023 15:05:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

21 7 2023 16:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

20 7 2023 15:04:53 提供 Nasdaq GlobeNewswire

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

13 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

03 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

26 6 2023 20:08:00 提供 Nasdaq GlobeNewswire

Coherus to Acquire Surface Oncology

16 6 2023 06:01:00 提供 Nasdaq GlobeNewswire

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

05 6 2023 16:30:00 提供 Nasdaq GlobeNewswire

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

01 6 2023 07:33:07 提供 Nasdaq GlobeNewswire

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

01 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

22 5 2023 07:30:00 提供 Nasdaq GlobeNewswire